Why Bright Minds Biosciences Inc.’s (DRUG) Stock Is Down 5.62%
As of Tuesday, September 15, Bright Minds Biosciences Inc.’s DRUG share price has dipped by 5.62%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Commentary & Analysis
Why Bright Minds Biosciences Inc.’s (DRUG) Stock Is Up 6.19%
As of Tuesday, August 25, Bright Minds Biosciences Inc.’s DRUG share price has surged by 6.19%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Bright Minds Biosciences Inc.’s (DRUG) Stock Is Up 7.87%
As of Friday, August 21, Bright Minds Biosciences Inc.’s DRUG share price has surged by 7.87%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Bright Minds Biosciences Inc.’s (DRUG) Stock Is Up 5.65%
As of Tuesday, August 04, Bright Minds Biosciences Inc.’s DRUG share price has surged by 5.65%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Bright Minds Biosciences Inc.’s (DRUG) Stock Is Down 5.31%
As of Monday, July 13, Bright Minds Biosciences Inc.’s DRUG share price has dipped by 5.31%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | DRUG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $489.0 | $250.1 | 37% |
|
| Shares Out (Mil) | 6.9 | 54.0 | 17% |
|
| Institutional Ownership | 86.3% | 93.1% | 54% |
|
| Float (Mil) | 6.7 | 41.4 | 15% |
|
| Beta | 0.09 | 0.95 | 8% |
|
| Avg Daily Volume (000s) | 118 | 661 | 37% |
|
| Price Change (52-week) |
(12.5%) | 49.5% | 41% |
|
| Growth | DRUG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 12.5% | na |
|
| Net Income (5yr) | (85.6%) | (10.1%) | 2% |
|
| EPS (5yr) | (20.7%) | 15.8% | 13 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 62.2% | (15.7%) | 96% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.953) | ($2.576) | ($5.751) | |
| Month Ago EPS | ($0.934) | ($2.558) | ($5.728) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($1.515) | ($4.243) | ($8.478) | |
| Year/Year Chg | 454.1% | 101.7% | 423.2% | |
| Financials | DRUG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($17) | ($44) | 25% |
|
| EPS (TTM) | ($2.007) | ($1.600) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($17) | ($33) | 16% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $535 | $175 | 35% |
|
| Valuation | DRUG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.31 | 2.36 | 58% |
|
| P/E | na | 18.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | DRUG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (74.8%) | na |
|
| ROA | (13.4%) | (47.6%) | 23% |
|
| ROE | (13.5%) | (54.9%) | 26% |
|
| Liabilities to Assets | 0.8% | 29.3% | 0% |
|
| F-Score | 2 | 3 | 7% |
|
Bright Minds Biosciences Inc. did not pass any screens on 10/2/2026.
